Comparative Pharmacology
Head-to-head clinical analysis: EPOGEN PROCRIT versus RETACRIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPOGEN PROCRIT versus RETACRIT.
EPOGEN/PROCRIT vs RETACRIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/dL).
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/dL.
None Documented
None Documented
Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance).
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent